CAN ADDITIONAL DRUG THERAPY ACCELERATE RESPONSE TIME TO ANTIDEPRESSANTS: A DO

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目及 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 具体目标： 1.为了评估碘甲状腺原氨酸或吲哚洛尔与SSRI同时开始是否可以加速治疗反应（即，提高速度）。 2.为了评估碘甲状腺原氨酸或吲哚洛尔与SSRI同时开始是否可以增加或增强治疗反应（即，在研究阶段结束时抑郁症状的更大减少）。 3.评估性别是否影响碘塞罗宁或吲哚洛尔的增强反应率的加速。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. SPECIFIC AIMS: 1. To assess whether the simultaneous commencement of liothyronine or pindolol to an SSRI can accelerate the treatment response (i.e., faster rate of improvement). 2. To assess whether the simultaneous commencement of liothyronine or pindolol to an SSRI can augment or enhance treatment response (i.e., greater reduction in depressive symptoms at end of study phase). 3. To assess whether gender influences the acceleration of augmentation response rate of liothyronine or pindolol.